Argent BioPharma Expands in Europe with German Approval for CannEpil™

Cannabinoid Therapy Gains Foothold in Germany’s Epilepsy Market

Argent BioPharma (ASX:RGT) has secured approval for its flagship cannabinoid-based epilepsy treatment, CannEpil™, to be prescribed in Germany. This milestone marks a major step in the company’s European expansion and strengthens its presence in one of the region’s key pharmaceutical markets.

Germany has approximately 816,000 epilepsy patients, many of whom struggle with drug-resistant forms of the condition. The approval of CannEpil™ under Germany’s special access scheme provides these patients with a new treatment option.

CEO Highlights Market Potential

Roby Zomer, Managing Director and CEO of Argent BioPharma, sees this approval as a game-changer for both the company and epilepsy patients in Germany.

“The approval of CannEpil™ in Germany represents a significant milestone for Argent BioPharma and the patients who rely on innovative treatments for epilepsy,” Zomer said.

 “This marks our continued expansion in Europe and reinforces our commitment to improving lives through cutting-edge cannabinoid-based medicine.”

The approval is expected to pave the way for further regulatory advancements across Europe, particularly in countries with similar access frameworks.

CannEpil™ Expands Access to Treatment

With this approval, physicians in Germany can now prescribe CannEpil™, potentially giving thousands of drug-resistant epilepsy patients access to a new therapeutic option.

Eligible patients may receive coverage through health insurance, depending on their physician’s recommendation and case assessment. This improves affordability and ensures broader access to CannEpil™ for those with limited treatment options.

Strengthening Argent BioPharma’s Market Position

Beyond patient access, this milestone reinforces Argent BioPharma’s leadership in neuroimmune modulation and cannabinoid-based therapeutics. The company has been developing treatments for central nervous system (CNS) disorders, with CannEpil™ leading the way.

This development also reflects the growing acceptance of cannabinoid-based medicine as a viable therapeutic option for CNS conditions such as refractory epilepsy.

Next Steps for Market Expansion

With CannEpil™ now approved in Germany, Argent BioPharma is focusing on key initiatives to ensure successful market penetration:

• Physician education programs: The company will engage with medical professionals across Germany to inform them about CannEpil™’s benefits and prescription pathways.
• Distribution expansion: Argent BioPharma will work with key partners to enhance CannEpil™’s accessibility throughout the country.
• Further regulatory approvals: Building on this success, the company will continue efforts to secure approval in additional European markets.
• Market performance monitoring: The company will track patient outcomes and market uptake to support ongoing research and development.

This approval is a pivotal achievement for Argent BioPharma, signalling growing acceptance of cannabinoid-based therapies in major pharmaceutical markets. The company continues to focus on expanding its presence and impact across Europe through science-driven innovation.

• About
• Latest Posts

Tim Grey

Latest posts by Tim Grey (see all)

• AML3D announces stronger FY26, with positive EBITDA reported in the second half - September 1, 2026
• Imagion Biosystems Advances MagSense® Phase 2 Trial - August 27, 2026
• Acrux-developed Menopause Hormone Therapy to enter Australian market - May 28, 2026